Clinical trials: Capecitabine
Colorectal Cancer
Bevacizumab and Combination Chemotherapy as First-Line Therapy in Treating Patients With Metastatic Colorectal Cancer That Cannot Be Removed By Surgery
RATIONALE: Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Trial name
- NCT00423696
- Testing
- bevacizumab, capecitabine, fluorouracil
- Where
- 15 sites in France
- Volunteers
- 145 people
- Sponsor
- UNICANCER
Breast Cancer
A Study of Herceptin (Trastuzumab) in Combination With Xeloda (Capecitabine) in Patients With Metastatic or Recurrent HER2-positive Breast Cancer After First-Line or (Neo)Adjuvant Therapy.
This single arm. open-label study will assess the efficacy and safety of Herceptin (trastuzumab) in combination with Xeloda (capecitabine) in patients with metastatic or recurrent HER2-positive breast cancer, refractory to or…
- Trial name
- NCT01290718
- Testing
- capecitabine [Xeloda], trastuzumab [Herceptin]
- Where
- 6 sites in Taiwan
- Volunteers
- 4 people
- Sponsor
- Hoffmann-La Roche
Unspecified Adult Solid Tumor, Protocol Specific, Cancer
Safety and Dosage Study of RAD001 (Everolimus) in Combination With Current Standard of Care to Treat Advanced Solid Tumors.
The purpose of this study is to determine if RAD001 (everolimus) helps improve the standard treatment of XELOX-A (bevacizumab, oxaliplatin, capecitabine) in advanced solid tumors.
- Trial name
- COBRA (NCT00849550)
- Testing
- capecitabine/oxaliplatin/bevacizumab/RAD001 (XELOX-A-Ev)
- Where
- 3 sites in United States
- Volunteers
- 32 people
- Sponsor
- Herbert Hurwitz
Estrogen Receptor Negative, HER2/Neu Negative
Platinum in Treating Patients With Residual Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy
This randomized phase III trial studies how well cisplatin or carboplatin (platinum based chemotherapy) works compared to capecitabine in treating patients with remaining (residual) basal-like triple-negative breast cancer…
- Conditions
- Estrogen Receptor Negative, HER2/Neu Negative, Invasive Breast Carcinoma, Progesterone Receptor Negative
- Trial name
- NCT02445391
- Testing
- Capecitabine, Carboplatin, Cisplatin
- Where
- 1,024 sites in United States, South Africa
- Volunteers
- 415 people
- Sponsor
- ECOG-ACRIN Cancer Research Group
Metastatic Gastric Cancer, Adenocarcinoma of the Gastro-oesophageal Junction
Docetaxel, Oxaliplatin, Capecitabine, Bevacizumab and Trastuzumab in Patients With Locally Advanced or Metastatic Gastric Cancer
Background: It is estimated that in the Netherlands each year approximately 900 patients with gastric cancer or adenocarcinoma of the gastro-oesophageal junction are candidates for chemotherapy.
- Trial name
- B-DOCT (NCT01359397)
- Testing
- Docetaxel, Oxaliplatin, Capecitabin, Bevacizumab, Docetaxel, Oxaliplatin, Capecitabin, Bevacizumab, Trastuzumab
- Where
- Netherlands
- Sponsor
- The Netherlands Cancer Institute
Gastrointestinal Neoplasm, Gastric Adenocarcinoma
First Line Study of Irinotecan, Capecitabine and Oxaliplatin in Metastatic Gastric or Gastroesophageal Cancer.
The investigators hypothesize IXO chemotherapy will have an improvement in response rate and acceptable toxicity for uncurable metastatic gastric cancer compared to historical controls.
- Trial name
- IXOGoo1 (NCT01129310)
- Testing
- Irinotecan-Capecitabine-Oxaliplatin
- Where
- Canada
- Volunteers
- 47 people
- Sponsor
- AHS Cancer Control Alberta
Biliary Tract Cancer (CCA), Intrahepatic Cholangiocarcinoma
Immunotherapy With Durva and Treme With or Without Capecitabine in Adjuvant Treatment for Biliary Tract Cancer
This is an interventional, prospective multicenter, open-label, phase II study in patients after curative surgery for BTC in a classic adjuvant situation, consisting of a two arm feasibility pilot part with a randomized…
- Conditions
- Biliary Tract Cancer (CCA), Intrahepatic Cholangiocarcinoma, Hilar Cholangiocarcinoma, Distal Cholangiocarcinoma
- Trial name
- NCT05239169
- Testing
- Durvalumab, Tremelimumab, Capecitabine
- Where
- Germany
- Volunteers
- 40 people
- Sponsor
- Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Breast Cancer
A Study to Evaluate Vinorelbine Plus Capecitabine Combined With Trastuzumab for HER2 Positive Patients Following Neoadjuvant Chemotherapy
This study aims to evaluate vinorelbine plus capecitabine combined with trastuzumab versus trastuzumab alone as the adjuvant Treatment of HER2 positive patients following neoadjuvant chemotherapy
- Trial name
- NCT04302441
- Testing
- Vinorelbine, Capecitabine
- Where
- China
- Volunteers
- 550 people
- Sponsor
- Fudan University
Local Advanced High Risk Nasopharyngeal Carcinoma
Concurrent Cisplatin Chemoradiation With or Without Capecitabine as Adjuvant Chemotherapy in Local Advanced High Risk Nasopharyngeal Carcinoma: Randomized Control Clinical Trial
This is an randomized controlled, multicenter clinical trial. The purpose of this study is to evaluate acute toxicity and efficacy of concurrent cisplatin chemoradiation with or without capecitabine as adjuvant chemotherapy in…
- Trial name
- NCT02143388
- Testing
- IMRT combine with cisplatin concurrent chemotherapy, IMRT combine with cisplatin concurrent chemotherapy plus capecitabine adjuvant chemotherapy
- Where
- China
- Volunteers
- 180 people
- Sponsor
- Zhao Chong
Gastric Cancer
Optimal Duration of Oxaliplatin in Adjuvant XELOX for Gastric Cancer Patients (EXODOX)
This study aims to compare the efficacy and safety of reduced adjuvant XELOX treatment (4 cycles of XELOX followed by 4 cycles of capecitabine alone) to standard adjuvant XELOX treatment (8 cycles of XELOX).
- Trial name
- NCT04787354
- Testing
- Oxaliplatin, Capecitabine
- Where
- South Korea
- Volunteers
- 976 people
- Sponsor
- Hallym University Medical Center
Nasopharyngeal Neoplasms
Anlotinib, Penpulimab and Capecitabine in Recurrent/Metastatic Nasopharyngeal Carcinoma
First-diagnosed metastasis or recurrence/metastasis NPC Patients will be treated with anlotinib, penpulimab and capecitabine.
- Trial name
- ALTER-HN005 (NCT05807880)
- Testing
- The combination treatment of anlotinib, penpulimab and capecitabine.
- Where
- China
- Volunteers
- 59 people
- Sponsor
- Sun Yat-sen University
Breast Neoplasm Malignant Female
Study of the Impact of DPD Activity on the Efficacy of Capecitabine
This study evaluates the Impact of DihydroPyrimidine Dehydrogenase (DPD) activity on the efficacy of Capecitabine in patients with metastatic breast cancer.
- Trial name
- DPDMAX (NCT04198727)
- Testing
- DPD activity assessment, Capecitabine
- Where
- 5 sites in France, Monaco
- Volunteers
- 155 people
- Sponsor
- Centre Antoine Lacassagne
Metastatic Breast Cancer
Study of Eniluracil + 5-Fluorouracil (5-FU) + Leucovorin Versus Capecitabine in Metastatic Breast Cancer
The purpose of the study is to determine if eniluracil/5-FU/leucovorin in metastatic breast cancer (MBC) may have efficacy and tolerability advantages over capecitabine monotherapy.
- Trial name
- NCT01231802
- Testing
- Eniluracil, 5-Fluorouracil, Leucovorin
- Where
- 16 sites in United States, Russia
- Volunteers
- 140 people
- Sponsor
- Adherex Technologies, Inc.
Colorectal Cancer
An Observational Study of Xeloda (Capecitabine) Monotherapy in Patients With Colorectal Cancer (AXEL)
This observational study will evaluate Xeloda (capecitabine) monotherapy on the effect of disease-free survival in patients with colon cancer stage III (Duke C) after surgical resection. Data will be collected for 3 years.
- Trial name
- NCT01276405
- Where
- Romania
- Volunteers
- 123 people
- Sponsor
- Hoffmann-La Roche
Adenocarcinoma of the Pancreas, Adenocarcinoma of the Stomach
Veliparib, Oxaliplatin, and Capecitabine in Treating Patients With Advanced Solid Tumors
This phase I trial is studying the side effects and the best dose of veliparib when given together with capecitabine and oxaliplatin in treating patients with advanced solid tumors.
- Conditions
- Adenocarcinoma of the Pancreas, Adenocarcinoma of the Stomach, BRCA1 Mutation Carrier, BRCA2 Mutation Carrier
- Trial name
- NCT01233505
- Testing
- veliparib, capecitabine, oxaliplatin
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- National Cancer Institute (NCI)
Colorectal Cancer
A Study of Capecitabine (Xeloda) and Bevacizumab as a First-line Therapy in Patients With Metastatic Colorectal Cancer
This 4 arm study assessed the efficacy and safety of oral capecitabine (Xeloda) or intravenous (iv) fluorouracil/leucovorin, in combination with iv oxaliplatin (Eloxatin) with or without iv bevacizumab (Avastin), as a first-line…
- Trial name
- NCT00069095
- Testing
- Oxaliplatin 130 mg/m^2, Capecitabine 1000 mg/m^2, Bevacizumab 7.5 mg/kg
- Where
- 236 sites in United States, Australia and 31 more
- Volunteers
- 2,035 people
- Sponsor
- Hoffmann-La Roche
Stomach Neoplasms, Paclitaxel
Intraperitoneal Paclitaxel With XELOX in Gastric Cancer With Peritoneal Metastasis
IPXELOX will investigate the safety, tolerability, and antitumor activity of intraperitoneal paclitaxel in combination with chemotherapy in patients with advanced gastric cancer with peritoneal metastasis.
- Conditions
- Stomach Neoplasms, Paclitaxel, Peritoneal Metastases
- Trial name
- IPXELOX (NCT04943653)
- Testing
- Paclitaxel
- Where
- South Korea
- Volunteers
- 61 people
- Sponsor
- Seoul St. Mary's Hospital
Malignancies
Study of Satraplatin With Capecitabine to Treat Advanced Solid Malignancies
The purpose of this study is to determine the maximally tolerated dose (MTD) and Phase 2 recommended dose of satraplatin when administered in combination with capecitabine in patients with advanced solid malignancies.
- Trial name
- NCT00329329
- Testing
- satraplatin and capecitabine
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Agennix
Advanced and Metastatic Breast Cancer
PK and Drug Interaction Study of Utidelone Plus Capecitabine in Patients With Advanced Breast Cancer
This trial is an open, multi-center, phase Ic clinical study on the pharmacokinetics and drug interactions of utidelone injection combined with capecitabine in patients with recurrent and metastatic breast cancer.
- Trial name
- NCT05052437
- Testing
- Utidelone Injection; capecitabine, Utidelone
- Where
- 2 sites in China
- Volunteers
- 16 people
- Sponsor
- Beijing Biostar Pharmaceuticals Co., Ltd.
Colorectal Neoplasms
Study of Andrographolides With or Without Capecitabine to Treat Colorectal Cancer
The purpose of this study is to determine the efficacy and safety of Andrographolides combined with Capecitabine in treatment of elderly patients with locally advanced or recurrent or metastasis inoperable colorectal cancer
- Trial name
- AGCRC-013 (NCT01993472)
- Testing
- Andrographolides, Capecitabine
- Where
- China
- Volunteers
- 308 people
- Sponsor
- Gu Yanhong